NASDAQ:BFRABIOFRONTERA AG/ADR Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOFRONTERA AG/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.51 -0.01 (-0.15 %) (As of 06/2/2020 04:00 PM ET) Add Compare Share Today's Range$6.51Now: $6.51▼$7.0050-Day Range$5.41MA: $6.31▼$7.0952-Week Range$5.41Now: $6.51▼$18.32Volume1,000 shsAverage Volume2,009 shsMarket Capitalization$145.99 millionP/E RatioN/ADividend YieldN/ABeta0.78 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsInstitutional OwnershipHeadlinesSocial Media Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBIOFRONTERA AG/ADR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, BIOFRONTERA AG/ADR has a potential upside of 45.9% from its current price of $6.51.Amount of Analyst CoverageBIOFRONTERA AG/ADR has only been the subject of 2 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesBIOFRONTERA AG/ADR has received 139 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBIOFRONTERA AG/ADR has received 142 “underperform” votes. (Add your “underperform” vote.)Community SentimentBIOFRONTERA AG/ADR has received 50.53% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BIOFRONTERA AG/ADR and other stocks. Vote “Outperform” if you believe BFRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BFRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBIOFRONTERA AG/ADR does not currently pay a dividend.Dividend GrowthBIOFRONTERA AG/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOFRONTERA AG/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 0.21% of the stock of BIOFRONTERA AG/ADR is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOFRONTERA AG/ADR is -12.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOFRONTERA AG/ADR is -12.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOFRONTERA AG/ADR has a P/B Ratio of 13.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.20 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BFRA Previous Symbol CUSIPN/A CIKN/A Webwww.biofrontera.com Phone011-49-2148-7600Debt Debt-to-Equity Ratio2.22 Current Ratio1.94 Quick Ratio1.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.02 million Price / Sales4.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book13.02Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-8,240,000.00 Net Margins-34.52% Return on Equity-64.65% Return on Assets-14.85%Miscellaneous Employees149 Outstanding Shares22,425,000Market Cap$145.99 million Next Earnings Date8/25/2020 (Estimated) OptionableNot Optionable NASDAQ:BFRA Rates by TradingView Receive BFRA News and Ratings via Email Sign-up to receive the latest news and ratings for BFRA and its competitors with MarketBeat's FREE daily newsletter. BIOFRONTERA AG/ADR (NASDAQ:BFRA) Frequently Asked Questions How has BIOFRONTERA AG/ADR's stock been impacted by COVID-19 (Coronavirus)? BIOFRONTERA AG/ADR's stock was trading at $9.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BFRA shares have decreased by 29.8% and is now trading at $6.51. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of BIOFRONTERA AG/ADR? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOFRONTERA AG/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIOFRONTERA AG/ADR. When is BIOFRONTERA AG/ADR's next earnings date? BIOFRONTERA AG/ADR is scheduled to release its next quarterly earnings announcement on Tuesday, August 25th 2020. View our earnings forecast for BIOFRONTERA AG/ADR. How were BIOFRONTERA AG/ADR's earnings last quarter? BIOFRONTERA AG/ADR (NASDAQ:BFRA) posted its earnings results on Monday, April, 29th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The company had revenue of $7.48 million for the quarter. BIOFRONTERA AG/ADR had a negative net margin of 34.52% and a negative return on equity of 64.65%. View BIOFRONTERA AG/ADR's earnings history. How often does BIOFRONTERA AG/ADR pay dividends? What is the dividend yield for BIOFRONTERA AG/ADR? BIOFRONTERA AG/ADR declared a -- dividend on Wednesday, March 18th. Investors of record on Thursday, March 19th will be paid a dividend of $0.0221 per share on Monday, March 30th. The ex-dividend date of this dividend is Wednesday, March 18th. View BIOFRONTERA AG/ADR's dividend history. What price target have analysts set for BFRA? 2 brokerages have issued 1-year price objectives for BIOFRONTERA AG/ADR's stock. Their forecasts range from $8.00 to $11.00. On average, they expect BIOFRONTERA AG/ADR's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 45.9% from the stock's current price. View analysts' price targets for BIOFRONTERA AG/ADR. Has BIOFRONTERA AG/ADR been receiving favorable news coverage? News stories about BFRA stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIOFRONTERA AG/ADR earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near future. View the latest news aboutBIOFRONTERA AG/ADR. Who are some of BIOFRONTERA AG/ADR's key competitors? Some companies that are related to BIOFRONTERA AG/ADR include Athersys (ATHX), Passage Bio (IMRA), Frequency Therapeutics (FREQ), Passage Bio (KROS), Trillium Therapeutics (TRIL), Aprea Therapeutics (APRE), Corbus Pharmaceuticals (CRBP), Clovis Oncology (CLVS), Crinetics Pharmaceuticals (CRNX), Basilea Pharmaceutica (BPMUF), Zafgen (ZFGN), Viking Therapeutics (VKTX), AC Immune (ACIU), AnaptysBio (ANAB) and Atreca (BCEL). View all competitors. What other stocks do shareholders of BIOFRONTERA AG/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOFRONTERA AG/ADR investors own include GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Gilead Sciences (GILD), GlaxoSmithKline (GSK), Supernus Pharmaceuticals (SUPN), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), Allergan (AGN), Akari Therapeutics (AKTX) and Autolus Therapeutics (AUTL). Who are BIOFRONTERA AG/ADR's key executives? BIOFRONTERA AG/ADR's management team includes the following people: Prof. Hermann Lübbert, Co-Founder, Chairman of Management Board & CEO (Age 63)Mr. Thomas Schaffer, CFO & Member of Management Board (Age 56)Mr. Christoph Dünwald, Chief Commercial Officer, Head of Sales & Marketing and Additional Member of Management Board (Age 51)Mr. Alexander Richardson, Head of UK Sales Team When did BIOFRONTERA AG/ADR IPO? (BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. What is BIOFRONTERA AG/ADR's stock symbol? BIOFRONTERA AG/ADR trades on the NASDAQ under the ticker symbol "BFRA." Who are BIOFRONTERA AG/ADR's major shareholders? BIOFRONTERA AG/ADR's stock is owned by a number of retail and institutional investors. Top institutional investors include Sowell Financial Services LLC (0.20%). Which major investors are buying BIOFRONTERA AG/ADR stock? BFRA stock was purchased by a variety of institutional investors in the last quarter, including Sowell Financial Services LLC. How do I buy shares of BIOFRONTERA AG/ADR? Shares of BFRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BIOFRONTERA AG/ADR's stock price today? One share of BFRA stock can currently be purchased for approximately $6.51. How big of a company is BIOFRONTERA AG/ADR? BIOFRONTERA AG/ADR has a market capitalization of $145.99 million and generates $35.02 million in revenue each year. BIOFRONTERA AG/ADR employs 149 workers across the globe. What is BIOFRONTERA AG/ADR's official website? The official website for BIOFRONTERA AG/ADR is www.biofrontera.com. How can I contact BIOFRONTERA AG/ADR? BIOFRONTERA AG/ADR's mailing address is HEMMELRATHER WEG 201, LEVERKUSEN 2M, D-51377. The company can be reached via phone at 011-49-2148-7600 or via email at [email protected] This page was last updated on 6/3/2020 by MarketBeat.com Staff
